[Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies]

Hui Tang; Mei Guan; Zhao Sun; Chun Mei Bai

doi:10.3881/j.issn.1000-503X.11534

[Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies]

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2020 Dec 30;42(6):825-830. doi: 10.3881/j.issn.1000-503X.11534.

[Article in Chinese]

Authors

Hui Tang¹, Mei Guan¹, Zhao Sun¹, Chun Mei Bai¹

Affiliation

¹ Department of Oncology,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.

PMID: 33423733
DOI: 10.3881/j.issn.1000-503X.11534

Abstract

While immune checkpoint inhibitors(ICIs)are effective and promising treatments for a variety of malignancies,they also have safety concerns,especially the immune-related adverse events(irAEs).Unlike the side effects of traditional chemotherapy and targeted therapy,irAEs are adverse events caused by immune activation after ICIs treatment and thus may involve almost every system of the body.Therefore,biomarkers for predicting irAEs after ICIs treatment are urgently needed.Here we review the currently available predictive biomarkers of irAEs.

Keywords: biomarker; cancer; immune checkpoint inhibitors; immune-related adverse events.

Publication types

Review

MeSH terms

Biomarkers*
Humans
Immune Checkpoint Inhibitors / adverse effects*
Immunotherapy / adverse effects
Neoplasms* / drug therapy

Substances

Biomarkers
Immune Checkpoint Inhibitors